MicroRNA‑222‑3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with an unfavorable prognosis of patients with renal cell carcinoma Corrigendum in /10.3892/ijmm.2024.5377

Zhao,Liwen; Quan,Jing; Li,Zuwei; Pan,Xiang; Wang,Jingyao; Xu,Jinling; Xu,Weijie; Guan,Xin; Li,Hang; Yang,Shangqi; Gui,Yaoting; Chen,Yun; Lai,Yongqing

doi:10.3892/ijmm.2018.3931

MicroRNA‑222‑3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with an unfavorable prognosis of patients with renal cell carcinoma

Corrigendum in: /10.3892/ijmm.2024.5377

Authors:
- Liwen Zhao
- Jing Quan
- Zuwei Li
- Xiang Pan
- Jingyao Wang
- Jinling Xu
- Weijie Xu
- Xin Guan
- Hang Li
- Shangqi Yang
- Yaoting Gui
- Yun Chen
- Yongqing Lai
View Affiliations

Affiliations: Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen Hospital, Shenzhen PKU‑HKUST Medical Center, Shenzhen, Guangdong 518036, P.R. China, Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China, Department of Ultrasound, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: October 15, 2018 https://doi.org/10.3892/ijmm.2018.3931
Pages: 525-534

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of microRNA (miR)‑222‑3p in renal cell carcinoma (RCC). The expression level of miR‑222‑3p was detected in RCC tissues and cell lines (ACHN, 786‑O, Caki‑1 and 769‑P) and was identified to be significantly upregulated compared with the level in adjacent normal renal tissues and HK‑2 cells. Further in vitro experiments demonstrated that the overexpression of miR‑222‑3p promoted the migration and invasion, and attenuated the apoptosis of 786‑O cells, whereas the knockdown of miR‑222‑3p suppressed the migration and invasion and induced the apoptosis of 786‑O cells. Similar results were observed in the ACHN cell line in terms of migration, invasion and apoptosis. Furthermore, the expression level of miR‑222‑3p was measured in 42 RCC formaldehyde‑fixed paraffin‑embedded samples, and the association between the expression of miR‑222‑3p and the pathological characteristics and overall survival rate of patients with RCC was analyzed. The results demonstrated that patients with a higher expression of miR‑222‑3p had a significantly lower overall survival rate, compared with those with a lower expression of miR‑222‑3p [hazard ratio (HR)=5.120; P=0.036]. Multivariate analysis identified that patients with a higher expression of miR‑222‑3p retained the statistically significant decrease in overall survival rate compared with patients with a lower expression of miR‑222‑3p (HR=5.636; P=0.030). Furthermore, Kaplan‑Meier survival curves indicated that patients with higher miR‑222‑3p had significantly lower overall survival rates compared with patients with lower miR‑222‑3p (P=0.020). Taken together, these results suggested that miR‑222‑3p serves as an onco‑miR in RCC and may be a potential prognostic biomarker and therapeutic target in patients with RCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Brugarolas J: Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol. 32:1968–1976. 2014. View Article : Google Scholar : PubMed/NCBI
3	Rossi SH, Klatte T, Usher-Smith J and Stewart GD: Epidemiology and screening for renal cancer. World J Urol. 36:1341–1353. 2018. View Article : Google Scholar : PubMed/NCBI
4	Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
5	Karbasforooshan H, Roohbakhsh A and Karimi G: SIRT1 and microRNAs: The role in breast, lung and prostate cancers. Exp Cell Res. 367:1–6. 2018. View Article : Google Scholar : PubMed/NCBI
6	Kian R, Moradi S and Ghorbian S: Role of components of microRNA machinery in carcinogenesis. Exp Oncol. 40:2–9. 2018.PubMed/NCBI
7	Fan Y, Ma X, Li H, Gao Y, Huang Q, Zhang Y, Bao X, Du Q, Luo G, Liu K, et al: miR-122 promotes metastasis of clear-cell renal cell carcinoma by downregulating Dicer. Int J Cancer. 142:547–560. 2018. View Article : Google Scholar
8	Kabir TD, Ganda C, Brown RM, Beveridge DJ, Richardson KL, Chaturvedi V, Candy P, Epis M, Wintle L, Kalinowski F, et al: A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma. Hepatology. 67:216–231. 2018. View Article : Google Scholar
9	Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW and Yang BB: MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene. 30:806–821. 2011. View Article : Google Scholar
10	Jia YJ, Liu ZB, Wang WG, Sun CB, Wei P, Yang YL, You MJ, Yu BH, Li XQ and Zhou XY: HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma. Leukemia. 32:703–711. 2018. View Article : Google Scholar
11	Ferreira AF, Calin GA, Picanco-Castro V, Kashima S, Covas DT and de Castro FA: Hematopoietic stem cells from induced pluripotent stem cells-considering the role of microRNA as a cell differentiation regulator. J Cell Sci. 131:pii: jcs2030182018. View Article : Google Scholar
12	Kim S, Lee E, Jung J, Lee JW, Kim HJ, Kim J, Yoo HJ, Lee HJ, Chae SY, Jeon SM, et al: microRNA-155 positively regulates glucose metabolism via PIK3R1-FOXO3a-cMYC axis in breast cancer. Oncogene. 37:2982–2991. 2018. View Article : Google Scholar : PubMed/NCBI
13	Hu W, Tan C, He Y, Zhang G, Xu Y and Tang J: Functional miRNAs in breast cancer drug resistance. Onco Targets Ther. 11:1529–1541. 2018. View Article : Google Scholar : PubMed/NCBI
14	Hosseinahli N, Aghapour M, Duijf PHG and Baradaran B: Treating cancer with microRNA replacement therapy: A literature review. J Cell Physiol. 233:5574–5588. 2018. View Article : Google Scholar : PubMed/NCBI
15	Bhat NS, Colden M, Dar AA, Saini S, Arora P, Shahryari V, Yamamura S, Tanaka Y, Kato T, Majid S and Dahiya R: MicroRNA-720 regulates E-cadherin-αE-catenin complex and promotes renal cell carcinoma. Mol Cancer Ther. 16:2840–2848. 2017. View Article : Google Scholar : PubMed/NCBI
16	Dasgupta P, Kulkarni P, Majid S, Shahryari V, Hashimoto Y, Bhat NS, Shiina M, Deng G, Saini S, Tabatabai ZL, et al: MicroRNA-203 inhibits long noncoding RNA HOTAIR and regulates tumorigenesis through epithelial-to-mesenchymal transition pathway in renal cell carcinoma. Mol Cancer Ther. 17:1061–1069. 2018. View Article : Google Scholar : PubMed/NCBI
17	Han Z, Zhang Y, Sun Y, Chen J, Chang C, Wang X and Yeh S: ERβ-mediated alteration of circATP2B1 and miR-204-3p signaling promotes invasion of clear cell renal cell carcinoma. Cancer Res. 78:2550–2563. 2018. View Article : Google Scholar : PubMed/NCBI
18	Wang M, Sun Y, Xu J, Lu J, Wang K, Yang DR, Yang G, Li G and Chang C: Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling. Int J Cancer. 143:100–112. 2018. View Article : Google Scholar : PubMed/NCBI
19	Tan X, Tang H, Bi J, Li N and Jia Y: MicroRNA-222-3p associated with Helicobacter pylori targets HIPK2 to promote cell proliferation, invasion, and inhibits apoptosis in gastric cancer. J Cell Biochem. 119:5153–5162. 2018. View Article : Google Scholar
20	Li Q, Shen K, Zhao Y, He X, Ma C, Wang L, Wang B, Liu J and Ma J: MicroRNA-222 promotes tumorigenesis via targeting DKK2 and activating the Wnt/β-catenin signaling pathway. FEBS Lett. 587:1742–1748. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, Sekido Y, Kondo M and Hasegawa Y: Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Med. 4:551–564. 2015. View Article : Google Scholar : PubMed/NCBI
22	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Barata PC and Rini BI: Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 67:507–524. 2017. View Article : Google Scholar : PubMed/NCBI
25	Lightell DJ Jr, Moss SC and Woods TC: Upregulation of miR-221 and -222 in response to increased extracellular signal-regulated kinases 1/2 activity exacerbates neointimal hyperplasia in diabetes mellitus. Atherosclerosis. 269:71–78. 2018. View Article : Google Scholar
26	Zhao X, Wang P, Liu J, Zheng J, Liu Y, Chen J and Xue Y: Gas5 exerts tumor-suppressive functions in Human Glioma cells by targeting miR-222. Mol Ther. 23:1899–1911. 2015. View Article : Google Scholar : PubMed/NCBI
27	Gao H, Cong X, Zhou J and Guan M: MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer. Cancer Cell Int. 17:782017. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Yao J, Huan L, Lian J, Bao C, Li Y, Ge C, Li J, Yao M, Liang L and He X: GNAI3 inhibits tumor cell migration and invasion and is post-transcriptionally regulated by miR-222 in hepatocellular carcinoma. Cancer Lett. 356:978–984. 2015. View Article : Google Scholar
29	Lv S, Xue J, Wu C, Wang L, Wu J, Xu S, Liang X and Lou J: Identification of A panel of serum microRNAs as biomarkers for early detection of lung adenocarcinoma. J Cancer. 8:48–56. 2017. View Article : Google Scholar : PubMed/NCBI
30	Lee C, He H, Jiang Y, Di Y, Yang F, Li J, Jin C and Fu D: Elevated expression of tumor miR-222 in pancreatic cancer is associated with Ki67 and poor prognosis. Med Oncol. 30:7002013. View Article : Google Scholar : PubMed/NCBI
31	Han SH, Kim HJ, Gwak JM, Kim M, Chung YR and Park SY: MicroRNA-222 expression as a predictive marker for tumor progression in hormone receptor-positive breast cancer. J Breast Cancer. 20:35–44. 2017. View Article : Google Scholar : PubMed/NCBI
32	Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F and Sánchez-Carbayo M: miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 180:1808–1815. 2012. View Article : Google Scholar : PubMed/NCBI
33	Chang YA, Weng SL, Yang SF, Chou CH, Huang WC, Tu SJ, Chang TH, Huang CN, Jong YJ and Huang HD: A Three-MicroRNA signature as a potential biomarker for the early detection of oral cancer. Int J Mol Sci. 19:pii: E7582018. View Article : Google Scholar
34	Kafshdooz L, Pourfathi H, Akbarzadeh A, Kafshdooz T, Razban Z, Sheervalilou R, Ebrahimi Sadr N, Khalilov R, Saghfi S, Kavetskyy T, et al: The role of microRNAs and nanoparticles in ovarian cancer: A review. Artif Cells Nanomed Biotechnol. 1–7. 2018.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
35	Meo AD, Saleeb R, Wala SJ, Khella HW, Ding Q, Zhai H, Krishan K, Krizova A, Gabril M, Evans A, et al: A miRNA-based classification of renal cell carcinoma subtypes by PCR and in situ hybridization. Oncotarget. 9:2092–2104. 2017.
36	Youssef YM, White NM, Grigull J, Krizova A, Samy C, Mejia-Guerrero S, Evans A and Yousef GM: Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol. 59:721–730. 2011. View Article : Google Scholar : PubMed/NCBI
37	Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C and Czarnecka AM: Choosing the right cell line for renal cell cancer research. Mol Cancer. 15:832016. View Article : Google Scholar : PubMed/NCBI